Introduction {#tmi12656-sec-0005}
============

An estimated 2.1 million adolescents (10--19 years of age) globally were living with HIV in 2012 [1](#tmi12656-bib-0001){ref-type="ref"}. HIV‐related deaths among adolescents are estimated to have tripled since 2000, making HIV the second leading cause of death among adolescents worldwide [2](#tmi12656-bib-0002){ref-type="ref"}. Coverage of antiretroviral therapy (ART) is significantly lower (34%) in adolescents and children than in adults [3](#tmi12656-bib-0003){ref-type="ref"}. With successful scale‐up of screening and treatment of infants infected with HIV, many of the \>500 000 HIV‐infected children who started on ART during infancy are surviving to adolescence, often with complex treatment needs.

Adolescence is accompanied by rapid physical, psychological and physiological changes which influence health‐related behaviour. Adolescents frequently find consistent, long‐term medication adherence difficult, and HIV treatment is no exception [4](#tmi12656-bib-0004){ref-type="ref"}, [5](#tmi12656-bib-0005){ref-type="ref"}, [6](#tmi12656-bib-0006){ref-type="ref"}. Maintaining sustained high levels of adherence to ART is the crux of successful treatment, preventing the development of drug resistance and disease progression, and decreasing risk of onward transmission once sexual debut occurs. Virological failure may also occur as a result of suboptimal drug dosing. Accurate weight‐based dosing is difficult to achieve during the growth spurt which occurs in adolescence, and frequent dose changes are necessary, which may be challenging in under‐staffed healthcare facilities in low‐resource settings, where the majority of HIV‐infected adolescents live, and can be confusing for the patient.

This review aimed to assess the proportion of adolescents taking ART in routine healthcare settings who achieve virological suppression in order to inform the need for interventions to optimise HIV outcomes in an age group that may be at high risk of treatment failure.

Methods {#tmi12656-sec-0006}
=======

This review was conducted in accordance with the standards of the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) group [7](#tmi12656-bib-0007){ref-type="ref"}. A detailed protocol was prepared. We included cohort studies, randomised controlled trials (RCTs) and cross‐sectional studies of adolescents taking ART that investigated the prevalence and/or rate of virological suppression. Studies were included if they reported on least 50 HIV‐infected adolescents (aged 10--19 years) receiving ART, or where the mean or median age of participants was between 10 and 19 years. Studies where neither the mean nor the median age was reported, or where data were not disaggregated by age, were excluded. No exclusions with regard to language or geographical area were applied.

A compound search strategy was developed (Table S1), and the following electronic databases were searched: Medline (OVID), Embase (OVID), Global Health (OVID) and Web of Science. Reference lists of all studies identified by the above methods, and bibliographies of relevant systematic reviews or meta‐analyses were examined. All references were imported into EndNote (Thompson Reuters), and duplicates were removed. Titles and abstracts were examined independently by two reviewers (RF and KK) to exclude studies that clearly did not meet inclusion criteria.

The full text of all potentially relevant studies was obtained, and the inclusion criteria were applied using a pre‐tested eligibility form. Data extraction was independently performed by two reviewers (RF and KK) using a standardised data extraction form. The following information was obtained for included studies: start and end dates of the study; study design; location (country, healthcare setting); rate/proportion of participants who died or were lost to follow‐up; age; sex; CD4 cell count at ART initiation; ART regimen; median duration of follow‐up; median duration on ART; laboratory method for HIV viral load measurement; viral load threshold used to define suppression; proportion of participants with viral load ascertained; proportion of participants with virological suppression at 12, 24, 36 months; and overall proportion with virological suppression.

Primary outcomes were proportions of adolescents with suppressed viral load at 12 and 24 months of starting ART. Secondary outcomes included proportion with virological suppression irrespective of time on ART and rate of virological suppression. Virological suppression was defined as by the definitions used by the authors of the study.

A modified Newcastle‐Ottawa Scale was used to assess the risk of bias [8](#tmi12656-bib-0008){ref-type="ref"}. A scoring scale to evaluate potential sources of bias was used. It included risk of selection bias; method of viral load testing; recording of baseline characteristics; duration of ART and follow‐up; proportion of participants with missing outcomes; and appropriateness of analysis. Studies were scored on each these criteria with studies graded as providing good (score 7--8), moderate (score 5--6) or low quality of evidence (3--4), or serious risk of bias (\<3).

Results {#tmi12656-sec-0007}
=======

From a total of 5316 potentially relevant unique citations, 20 studies were included in this review (Figure S1). Of the 20 studies that were included, 7 (35%) were from Africa [9](#tmi12656-bib-0009){ref-type="ref"}, [10](#tmi12656-bib-0010){ref-type="ref"}, [11](#tmi12656-bib-0011){ref-type="ref"}, [12](#tmi12656-bib-0012){ref-type="ref"}, [13](#tmi12656-bib-0013){ref-type="ref"}, [14](#tmi12656-bib-0014){ref-type="ref"}, [15](#tmi12656-bib-0015){ref-type="ref"}, 8 (40%) were from North America [16](#tmi12656-bib-0016){ref-type="ref"}, [17](#tmi12656-bib-0017){ref-type="ref"}, [18](#tmi12656-bib-0018){ref-type="ref"}, [19](#tmi12656-bib-0019){ref-type="ref"} and Europe [20](#tmi12656-bib-0020){ref-type="ref"}, [21](#tmi12656-bib-0021){ref-type="ref"}, [22](#tmi12656-bib-0022){ref-type="ref"}, [23](#tmi12656-bib-0023){ref-type="ref"}, 3 (15%) were from Asia [24](#tmi12656-bib-0024){ref-type="ref"}, [25](#tmi12656-bib-0025){ref-type="ref"}, [26](#tmi12656-bib-0026){ref-type="ref"} and 2 (10%) were from Latin America [27](#tmi12656-bib-0027){ref-type="ref"}, [28](#tmi12656-bib-0028){ref-type="ref"} (Table [1](#tmi12656-tbl-0001){ref-type="table-wrap"}). Half (*n *= 10) were cohort studies, and half were cross‐sectional studies (*n *= 10). The studies were predominantly based on multicentre and/or multicountry research cohorts, or from urban, specialist centres. The cohorts included perinatally, sexually and parenterally infected adolescents.

###### 

Baseline characteristics of studies included in the review

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year                                                                                      Study period   Study setting                                                                                                                                             Study design   N     Age range (median age)                            \% Female       Mode of HIV acquisition                                 Median CD4 count at initiation (IQR), cells/μl   Median HIV viral load (log~10~) at initiation (IQR)
  ------------------------------------------------------------------------------------------------- -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- ----- ------------------------------------------------- --------------- ------------------------------------------------------- ------------------------------------------------ -----------------------------------------------------
  Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Bakeera‐Kitaka (2008) [9](#tmi12656-bib-0009){ref-type="ref"}                                     2004--2006     Uganda; Paediatric HIV Clinic, Mulago Hospital\                                                                                                           Cohort         118   10--19 years (13.6) at ART initiation             64%             Majority perinatal                                      124 (12--249)                                    5.4 (4.9--6.8)
                                                                                                                   Public sector                                                                                                                                                                                                                                                                                                                                             

  Evans (2013) [10](#tmi12656-bib-0010){ref-type="ref"}                                             2004--2010     South Africa; Public sector HIV clinics; 5 urban Gauteng province; 2 rural Mpumalanga                                                                     Cohort         652   10--19 years at ART initiation                    67%             Mixed                                                   109 (24--195):10--14 years\                      NR
                                                                                                                                                                                                                                                                                                                                                                                                                            133 (54--198): 15--19 years                      

  Nglazi (2012) [11](#tmi12656-bib-0011){ref-type="ref"}, [a](#tmi12656-note-0003){ref-type="fn"}   2002--2009     Cape Town, South Africa; Public sector community‐based ART programme[a](#tmi12656-note-0003){ref-type="fn"} ^,^ [b](#tmi12656-note-0004){ref-type="fn"}   Cohort         65    9--19 years (11.5) at cohort entry in 2009        66%             Mixed: 72% perinatal, 6% sexual, 2% other               134 (41--198)                                    4.8 (4.5--5.2)

  Nachega (2009) [12](#tmi12656-bib-0012){ref-type="ref"}                                           1999--2006     9 countries in southern Africa; Private‐sector, employer‐subsidised disease management programme 'Aid for AIDS'                                           Cohort         154   11--19 years (16.4) at ART initiation             73%             Sexual                                                  144 (27--246)                                    5.1 (4.5--5.6)

  Mutwa (2014) [13](#tmi12656-bib-0013){ref-type="ref"}                                             2009--2010     Kigali, Rwanda; University Teaching hospital                                                                                                              CS             424   1.7--18.8 years (10.8) at time of study           52%             Perinatal                                               NR                                               NR

  Sebunya (2013) [14](#tmi12656-bib-0014){ref-type="ref"}                                           2004--2009     Kampala, Uganda: JCRC‐HIV care and research institution                                                                                                   Cohort         236   10--18 years at ART initiation                    NR              Majority perinatal                                      135 (50--210): Unsuppressed\                     NR
                                                                                                                                                                                                                                                                                                                                                                                                                            130 (44--262): Suppressed                        

  Cutsem (2010) [15](#tmi12656-bib-0015){ref-type="ref"}                                            2000--2007     Cape Town, South Africa; Public sector primary care clinics supported by MSF                                                                              Cohort         86    10--19 years at ART initiation                    NR              NR                                                      127 (68--183)                                    NR

  Asia                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Chokephaibulkit (2014) [25](#tmi12656-bib-0025){ref-type="ref"}                                   2011           18 clinics in 6 Asian countries: TApHOD; public or university‐based paediatric HIV referral clinics; urban/semi‐urban                                     CS             987   12--18 years at the last clinic visit                             Perinatal                                               160 (30--337): 12--14 years\                     NR
                                                                                                                                                                                                                                                                                                                                                                                                                            98 (22--255) \>\>15 years                        

  Shet (2013) [26](#tmi12656-bib-0026){ref-type="ref"}                                              NR             Bangalore, India; tertiary care paediatric clinic                                                                                                         CS             80    2--16 years (10) at time of study                 38%             Perinatal                                               275                                              NR

  Zhao [24](#tmi12656-bib-0024){ref-type="ref"} (2011) [b](#tmi12656-note-0004){ref-type="fn"}      2006--2011     Henan province, China; rural national programme                                                                                                           CS             245   11--16 years (13.9) at time of study              33%             79% perinatal, 20% parenteral                           NR                                               NR

  South and Central America                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Santos Cruz (2011) [28](#tmi12656-bib-0028){ref-type="ref"}                                       2002--2006     15 sites in Brazil, Mexico and Argentina; NISDI cohort                                                                                                    Cohort         120   12--21 years (at time of enrolment into cohort)   55%             58% perinatal, 28% sexual, 8% transfusion, 6% unknown   NR                                               NR

  Santos Cruz (2014) [27](#tmi12656-bib-0027){ref-type="ref"}                                       2009--2011     5 regions in Brazil                                                                                                                                       CS             57    13--18 years at time of study                     NR              Perinatal                                               NR                                               NR

  North America                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Murphy (2005) [16](#tmi12656-bib-0016){ref-type="ref"}                                                           13 USA cities; REACH cohort                                                                                                                               CS             231   15--22 years (18.4) at time of study              73%             Sexual                                                  NR                                               NR

  Chandwani (2012) [17](#tmi12656-bib-0017){ref-type="ref"}                                         2003--2005     5 clinics in Washington/Baltimore /New York; Adolescent Impact Study                                                                                      CS             104   13--21 years (16.4) at time of study              54%             75% perinatal, 25% other                                NR                                               NR

  Van Dyke (2011) [18](#tmi12656-bib-0018){ref-type="ref"}                                          2007--2009     15 sites USA; PHACS AMP Cohort                                                                                                                            CS             451   7--16 years (12.2) at time of study               53%             Perinatal                                               CD4% 19 (12.25)                                  NR

  Flynn (2007) [19](#tmi12656-bib-0019){ref-type="ref"}                                             1999--2001     USA: multicentre research cohort PACTG 381                                                                                                                Cohort         120   11--22 years at ART initiation                    Approx. equal   Sexually‐infected                                       NR                                               NR

  Europe                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  De Mulder (2012) [20](#tmi12656-bib-0020){ref-type="ref"}                                         1997--2011     Madrid Cohort, Spain. Study at time of transfer to adult services                                                                                         CS             112   Mean age: 18.9 years at time of study             54%             94% perinatal                                           \<200: 64 (57%)\                                 NR
                                                                                                                                                                                                                                                                                                                                                                                                                            200--499: 37 (33%)\                              
                                                                                                                                                                                                                                                                                                                                                                                                                            \>500: 11 (10%)                                  

  Cohere (2008) [21](#tmi12656-bib-0021){ref-type="ref"}                                            1998--2006     30 European countries                                                                                                                                     Cohort         201   13--17 years (16.5) at time of study              63%             28% perinatal, 38% heterosexual, 4% IVDU, 3% gay        222 (110, 340)                                   4.8 (4.0, 5.2)

  Dollfus (2010) [22](#tmi12656-bib-0022){ref-type="ref"}                                                          90 health centres, France; EPF/ANRS C010 cohort                                                                                                           CS             210   10--17 years (15) at time of study                50%             Perinatal                                               NR                                               NR

  Judd (2007) [23](#tmi12656-bib-0023){ref-type="ref"}                                              1997--2006     UK/Ireland Centres: CHIPS Cohort                                                                                                                          Cohort         141   ≥10 years at ART initiation                       NR              NR                                                      NR                                               NR
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CD4 and VL at initiation of ART, except Nglazi: CD4/VL at cohort entry.

CS, Cross‐sectional; ART, antiretroviral therapy; IVDU, intravenous drug user; NR, Not reported, JCRC, Joint Clinical Research centre, MSF, Medicine Sans Frontieres, TApHOD, Treat Asia Pediatric HIV Observation Database, NISDI, NICHD International Site Development Initiative, REACH, Reaching for Excellence in Adolescence Care and Health, PHACS AMP, Pediatric HIV/AIDS Cohort Study. Adolescent Master Protocol, EPF/ANRS, French Perinatal Cohort, CHIPS, Collaborative HIV Pediatric Study.

Adolescent‐centred service (Nglazi: introduced 2008).

Age, mode of acquisition, gender, duration of ART refer to only the 76 participants of 245 who had virological failure.

John Wiley & Sons, Ltd

Only eight studies reported the proportion of adolescents that were virologically suppressed at a specified time point: six [9](#tmi12656-bib-0009){ref-type="ref"}, [10](#tmi12656-bib-0010){ref-type="ref"}, [11](#tmi12656-bib-0011){ref-type="ref"}, [12](#tmi12656-bib-0012){ref-type="ref"}, [21](#tmi12656-bib-0021){ref-type="ref"}, [23](#tmi12656-bib-0023){ref-type="ref"}, two [12](#tmi12656-bib-0012){ref-type="ref"}, [15](#tmi12656-bib-0015){ref-type="ref"} and one [19](#tmi12656-bib-0019){ref-type="ref"} study reported the proportion who were virologically suppressed at 12, 24 and 36 months after ART initiation, respectively (Table [2](#tmi12656-tbl-0002){ref-type="table-wrap"}). The remainder of the studies provided an overall proportion of virologically suppressed adolescents among those in care, without taking the duration of ART treatment into account.

###### 

Virological outcomes in HIV‐infected adolescents treated with antiretroviral therapy (ART)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                                              ART history & regimen              Median duration of follow‐up       Median duration of ART       Virological suppression cut‐off   Proportion of participant with viral load ascertained, %   Proportion virological suppressed, %   Overall proportion with virological suppression, %   Study quality          
  -------------------------------------------------------------------------------------------------- ---------------------------------- ---------------------------------- ---------------------------- --------------------------------- ---------------------------------------------------------- -------------------------------------- ---------------------------------------------------- --------------- ------ --------------------------------------------------
  Bakeera‐Kitaka (2008) [9](#tmi12656-bib-0009){ref-type="ref"}                                      Naive; 96% NNRTI‐based             NR                                 NR                           \<400                             72                                                         89                                                                                                                 [**\*\*\***](#tmi12656-note-0006){ref-type="fn"}

  Evans (2013) [10](#tmi12656-bib-0010){ref-type="ref"}, [a](#tmi12656-note-0007){ref-type="fn"}     Naive; 99% NNRTI‐based             NR                                 23.9 months: 10--14 years\   \<400                             21                                                         76                                                                                                                 [**\*\*\***](#tmi12656-note-0006){ref-type="fn"}
                                                                                                                                                                           15.6 months: 15--19 years                                                                                                                                                                                                                    

  Nglazi (2012) [11](#tmi12656-bib-0011){ref-type="ref"}, [b](#tmi12656-note-0008){ref-type="fn"}    Naive; 99% NNRTI‐based             34.6 months                        NR                           \<400                             52                                                         27                                                                                                                 [**\*\*\***](#tmi12656-note-0006){ref-type="fn"}

  Nachega (2009) [12](#tmi12656-bib-0012){ref-type="ref"}, [c](#tmi12656-note-0009){ref-type="fn"}   Naive; 92% NNRTI‐based             27 months                          NR                           \<400                             45, 25                                                     46                                     44                                                                          [**\*\*\***](#tmi12656-note-0006){ref-type="fn"}

  Mutwa (2014) [13](#tmi12656-bib-0013){ref-type="ref"}                                              On treatment; 99% NNRTI‐based      3.4 years                          NR                           \<40                              85                                                                                                                                                                     61     [**\*\*\***](#tmi12656-note-0006){ref-type="fn"}

  Sebunya (2013) [14](#tmi12656-bib-0014){ref-type="ref"}                                            On treatment; 100% NNRTI‐based     NR                                 NR                           \<400                             67                                                                                                                                                                     63     [**\*\*\***](#tmi12656-note-0006){ref-type="fn"}

  Cutsem (2010) [15](#tmi12656-bib-0015){ref-type="ref"}                                             Naive; NR                          NR                                 NR                           \<400                             NR                                                                                                87                                                                          [**\*\***](#tmi12656-note-0006){ref-type="fn"}

  Chokephaibulkit (2014) [25](#tmi12656-bib-0025){ref-type="ref"}                                    86% on first line treatment        NR                                 6.0 years (4.3--7.5)         \<400                             84                                                                                                                                                                     87     [**\*\*\***](#tmi12656-note-0006){ref-type="fn"}

  Zhao (2011) [24](#tmi12656-bib-0024){ref-type="ref"}                                               On treatment; 100% NNRTI‐based     NR                                 33.1 months                  \<50                              96                                                                                                                                                                     52     [**\*\*\***](#tmi12656-note-0006){ref-type="fn"}

  Shet (2013) [26](#tmi12656-bib-0026){ref-type="ref"}                                               On treatment; 100% NNRTI‐based     NT                                 31 months                    \<400                             82                                                                                                                                                                     85     [**\*\*\***](#tmi12656-note-0006){ref-type="fn"}

  Santos Cruz (2011) [28](#tmi12656-bib-0028){ref-type="ref"}                                        Treatment experienced; NR          34 months: vertically infected\    NR                           \<400                             97                                                                                                                                                                     37.5   [**\*\***](#tmi12656-note-0006){ref-type="fn"}
                                                                                                                                        35 months: horizontally infected                                                                                                                                                                                                                                                

  Santos Cruz (2014) [27](#tmi12656-bib-0027){ref-type="ref"}                                        Treatment experienced: NR          NR                                 7 years (mean)               \<50                              53                                                                                                                                                                     49     [**\*\***](#tmi12656-note-0006){ref-type="fn"}

  Flynn (2007) [19](#tmi12656-bib-0019){ref-type="ref"}                                              Treatment experienced: NR          NR                                 NR                           \<400                             37                                                                                                                                                     66                     [**\***](#tmi12656-note-0006){ref-type="fn"}

  Chandwani (2012) [17](#tmi12656-bib-0017){ref-type="ref"}                                          Treatment experienced: NR          NR                                 21% on ART for \< 1 years    \<400                             NR                                                                                                                                                                     28     [**\***](#tmi12656-note-0006){ref-type="fn"}

  Murphy (2005) [16](#tmi12656-bib-0016){ref-type="ref"}                                             Treatment experienced: NR          NR                                 NR                           \<10                              100                                                                                                                                                                    69     [**\*\***](#tmi12656-note-0006){ref-type="fn"}

  Van Dyke (2011) [18](#tmi12656-bib-0018){ref-type="ref"}                                           Highly treatment experienced; NR   NR                                 NR                                                             NR                                                                                                                                                                     68     [**\*\***](#tmi12656-note-0006){ref-type="fn"}

  De Mulder (2012) [20](#tmi12656-bib-0020){ref-type="ref"}                                          NR: Highly treatment experienced   15.6 years                         11.5 years                   \<200                             100                                                                                                                                                                    47     [**\*\*\***](#tmi12656-note-0006){ref-type="fn"}

  Judd (2007) [23](#tmi12656-bib-0023){ref-type="ref"}                                               Naive; NR                          NR                                 NR                           \<400                             53                                                         86                                                                                                                 [**\***](#tmi12656-note-0006){ref-type="fn"}

  Dollfus (2010) [22](#tmi12656-bib-0022){ref-type="ref"}                                            Highly treatment experienced; NR   NR                                 NR                           \<50                              96                                                                                                                                                                     43     [**\*\***](#tmi12656-note-0006){ref-type="fn"}

  Cohere (2008) [21](#tmi12656-bib-0021){ref-type="ref"}                                             Highly treatment experienced; NR   2.2 years                                                       \<50                              NR                                                         46                                                                                                                 [**\*\***](#tmi12656-note-0006){ref-type="fn"}
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

'Naive', not on treatment at start of study; NR, not reported.

Study quality: \*\*\*\*: good, \*\*\*: moderate, \*\*: low, \*: serious risk of bias.

33.7% changed regimens: 5% virological failure; 11% toxicity; 6% non‐adherence; 6% pregnancy).

Treatment failure rate (VL suppression followed by 2 subsequent VL \>1000 copies/ml): 8.2/100py.

Viral rebound after suppression 42% at 12 months (only among those with initially suppressed VL).
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In the six studies that reported this, the proportion of adolescents with virological suppression at 12 months after ART initiation varied from 27% to 89% (Table [2](#tmi12656-tbl-0002){ref-type="table-wrap"}). Virological suppression rates in studies not stratified by duration on ART ranged between 28% and 87%. Approximately one‐third of studies (*n *= 8) neither reported on the median duration on ART, nor on the median duration of follow‐up [9](#tmi12656-bib-0009){ref-type="ref"}, [14](#tmi12656-bib-0014){ref-type="ref"}, [15](#tmi12656-bib-0015){ref-type="ref"}, [16](#tmi12656-bib-0016){ref-type="ref"}, [18](#tmi12656-bib-0018){ref-type="ref"}, [19](#tmi12656-bib-0019){ref-type="ref"}, [22](#tmi12656-bib-0022){ref-type="ref"}, [23](#tmi12656-bib-0023){ref-type="ref"}. Four studies [15](#tmi12656-bib-0015){ref-type="ref"}, [17](#tmi12656-bib-0017){ref-type="ref"}, [18](#tmi12656-bib-0018){ref-type="ref"}, [21](#tmi12656-bib-0021){ref-type="ref"} did not record the completeness of outcome data, and two studies had a very high proportion of missing viral load data (79% and 63%) [10](#tmi12656-bib-0010){ref-type="ref"}, [19](#tmi12656-bib-0019){ref-type="ref"}. Overall most studies were scored as being moderate or low quality (Table [2](#tmi12656-tbl-0002){ref-type="table-wrap"}).

Discussion {#tmi12656-sec-0008}
==========

The main finding of this study was the paucity of data on virological outcomes among adolescents with HIV, despite more than 15 years of availability of combination ART. In included studies, there was substantial variation in the proportion of adolescents achieving virological suppression, and accurate overall estimates of the effectiveness of ART on viral suppression in this age group cannot be drawn because of this variability and the low to moderate quality of most studies. Thus, a meta‐analysis providing a pooled effect estimate was not attempted.

The studies included in this review illustrate some of the specific methodological issues encountered when analysing ART outcomes in children and adolescents, but also more general issues around analysis and reporting of ART outcomes. Any observational cohort study should be reported according to the STROBE (strengthening the reporting of observational studies in epidemiology) checklist, which has been endorsed by many high impact journals [29](#tmi12656-bib-0029){ref-type="ref"}, [30](#tmi12656-bib-0030){ref-type="ref"}. The STROBE checklist recommends that for each explanatory and outcome variable, the source of data and the methods of assessment (measurement) are described, the number of individuals at each stage of the study is clearly reported and the time of follow‐up is provided. Furthermore, the number of participants with missing data should be recorded and confounders taken into account [31](#tmi12656-bib-0031){ref-type="ref"}. Most of the studies included in this review did not provide all this information, hindering our ability to accurately identify the proportion of adolescents succeeding on ART. The responsibility of accurate reporting lies not only with the authors, but also with the wider scientific community including journal editors and peer reviewers. Some of the studies included in this review were published before the STROBE checklist was developed.

Even more critical is the fact that a number of the included cross‐sectional studies provided point estimates of viral load suppression without stratifying the results by time on ART. Several of these studies did not even report the mean or median time on ART [14](#tmi12656-bib-0014){ref-type="ref"}, [16](#tmi12656-bib-0016){ref-type="ref"}, [17](#tmi12656-bib-0017){ref-type="ref"}, [18](#tmi12656-bib-0018){ref-type="ref"}, [22](#tmi12656-bib-0022){ref-type="ref"}. Time on ART is highly likely to act as a confounder and cohorts with similar success rates, but different follow‐up times will appear to have different virological suppression rates. Thus, unstratified point prevalence estimates of virological suppression are meaningless, and we urge researchers to report results stratified by duration on ART in all future studies.

All included studies classified participants as adolescents according to their age at initiation of ART. A child starting ART on their eighth birthday will enter adolescence two years after ART initiation, whereas a child who starts ART at 6 months of age will have been on ART for 9.5 years before entering adolescence. Age‐updated analysis is therefore especially important when examining outcomes in children and adolescents. None of the studies included in the review attempted an age‐updated analysis. In practice, clinicians want to know the likelihood of virological suppression of a 14‐year old who has been taking ART for a few months, several years or over a decade. Clinicians are unlikely to assess patients aged 14 on the basis of having started ART as a child aged 1 year, 8 years or as adolescents aged 13. This information can only be obtained if age‐updated analyses are performed, alongside the analyses stratified by time on treatment discussed above.

A total of 21 studies included more than 50 adolescents on ART and reported on virological suppression, but did not provide adolescent‐specific suppression estimates but analysed adolescents together with children, which meant they had to be excluded. These studies could have contributed substantially to the body of evidence if age‐specific estimates had been provided. Furthermore, systematic reviews focus on peer‐reviewed published studies and thus are subject to publication bias. Due to heterogeneity of study designs and outcome definitions, summary estimates could not be calculated. Viral load testing methods have evolved over time, which makes comparison of studies across different periods and settings challenging. Further limitations of this review are the quality of studies included and high levels of missing data in some studies.

In conclusion, most available estimates of viral load suppression in adolescents are not very informative due to serious methodological concerns. Authors, journals and peer reviewers should be encouraged to follow the recommendation for observational cohort studies as laid out by the STROBE statement. We recommend the development of guidelines for ART cohort reporting focused on children, and adolescents to ensure data are analysed using generally accepted age groups such as 0, 1--4, 5--9, 10--14, 15--19 years, that time on ART is taken into account through stratified analyses, and that age‐updated analyses are conducted.
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**Figure S1** Selection process for the inclusion of studies.
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